经导管主动脉瓣再介入的当代发病率与手术量
该回顾性分析基于美国Medicare数据,评估2012年至2024年TAVR后再介入(redo TAVR和TAVR explant)的年发病率与手术量。结果显示redo TAVR和TAVR explant手术量持续增加,TAVR再介入年发病率从2019年0.17%升至2023年0.28%,且redo TAVR在初次TAVR5年后占主导。
要点
- TAVR再介入年发病率从2019年0.17%升至2023年0.28%。
- redo TAVR和TAVR explant手术量持续增加,尤其近年。
- 初次TAVR5年后,redo TAVR占再介入的88.5%。
核心结论
- redo TAVR和TAVR explant年手术量持续增加,尤其近年。
- redo TAVR常在初次TAVR5年后进行。
- 需未来分析以确定个体患者合适的TAVR再介入策略。
研究设计与样本
- 回顾性分析,数据来自美国Centers for Medicare & Medicaid Services Virtual Research Data Center,时间2012年1月至2024年6月。
- 纳入既往TAVR或SAVR后接受后续TAVR或SAVR的患者。
主要发现
- 自2020年以来,有1518例redo TAVR和1007例TAVR explant。
- TAVR再介入年发病率从2019年0.17%变为2023年0.28%。
- redo TAVR最常见时间间隔为初次TAVR后3个月内(410/2374 [17.3%]),TAVR explant为1至2年(259/1346 [19.2%])。
- 初次TAVR5年后,redo TAVR占再介入的725/819 [88.5%]。
临床怎么用
- 心内科医生应关注TAVR术后再介入的上升趋势,尤其5年后redo TAVR可能性高。
- 对于TAVR术后患者,需长期随访以评估再介入时机与策略。
局限性
- 回顾性分析,数据来源于美国Medicare,可能存在选择偏倚和编码不准确。
- 未提供再介入的具体适应证和患者个体化因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Transcatheter aortic valve replacement (TAVR) reintervention is performed by either redo TAVR or TAVR explant. There is insufficient data on contemporary TAVR reintervention procedural incidence and volume. OBJECTIVE: To evaluate contemporary procedural volumes of redo TAVR and TAVR explant. DESIGN, SETTING, AND PARTICIPANTS: This retrospective analysis of redo TAVR and TAVR explant annual incidence and procedural volume was performed from January 2012 to June 2024. For comprehensive assessment of aortic valve replacement, analysis of SAVR reintervention annual incidence and procedural volume was also performed. Data were obtained through the US Centers for Medicare & Medicaid Services Virtual Research Data Center. Patients with prior TAVR or SAVR who underwent subsequent TAVR or SAVR were included. EXPOSURES: Patients who underwent a TAVR after TAVR defined the redo TAVR group, while patients who underwent SAVR after TAVR defined the TAVR explant group. Patients who underwent a TAVR after SAVR defined the valve-in-valve (ViV) TAVR group, while patients who underwent SAVR after SAVR defined the redo SAVR group. Analysis of annual incidences and procedural volumes of all groups at different time intervals was conducted. MAIN OUTCOMES AND MEASURES: The primary outcome was annual incidence and procedural volume of both redo TAVR and TAVR explant. The secondary outcome was annual incidence and procedural volume of both ViV TAVR and redo SAVR. RESULTS: Of 410 720 total TAVRs from 2012 to 2024, 2374 redo TAVRs and 1346 TAVR explants were identified. Of 299 780 total SAVRs from 2012 to 2024, 5044 ViV-TAVRs and 4202 redo SAVRs were identified. Since 2020, there have been 1518 redo TAVRs and 1007 TAVR explants. The annual incidence of TAVR reintervention has changed from 0.17% in 2019 to 0.28% in 2023. Although the most common time interval for redo TAVR after index TAVR was within 3 months (410 of 2374 [17.3%]) and for TAVR explant after index TAVR was 1 to 2 years (259 of 1346 [19.2%]), redo TAVR was the predominant procedure beyond 5 years from the index TAVR (725 of 819 [88.5%]). CONCLUSIONS AND RELEVANCE: In this study, annual volumes of both redo TAVR and TAVR explant continued to increase, particularly in recent years. Redo TAVR is frequently performed over 5 years from the index TAVR. Future analysis to determine the appropriate TAVR reintervention strategy for individual patients is needed.
引用
- Braasch MC, Pyeatte SR, He J, et al. Contemporary Incidence and Procedural Volume of Transcatheter Aortic Valve Reintervention. JAMA Cardiol. 2025. PMID: 40991268. doi:10.1001/jamacardio.2025.3224
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。